TABLE 1.
Patients’ characteristics (n = 231)
| Parameters | Characteristics |
|---|---|
| Age at entry into the study (years) | 11 (7, 15) |
| Male | 107 (46.3) |
| Presence of CFRD | 119 (3.9) |
| Vitamin A serum levels (μg/dL) | 37.0 (29.0, 43.0) |
| BMI z‐score | 0.4 (−0.4, 1.1) |
| ppFEV1 | 97.0 (81.7, 107.2) |
| Liver involvement | |
| No involvement | 189 (81.8) |
| Non‐cirrhotic | 36 (15.6) |
| Cirrhosis | 6 (2.6) |
| Patients with CFTR modulators use | |
| Ivacaftor | 4 (1.7) |
| Lumacaftor/Ivacaftor | 23 (10.0) |
Data are shown as median (interquartile range) or n (%). CFRD, cystic fibrosis related diabetes; BMI, body mass index; ppFEV1, percent‐predicted forced expiratory volume in 1 second.